Clinical characteristics and prognostic factors in Chinese patients with classical Hodgkin’s lymphoma involving extranodal sites: a retrospective single-center study

References

• Eberle FC, Mani H, Jaffe ES. Histopathology of Hodgkin’s lymphoma. Cancer J. 2009;15(2):129–137. doi: 10.1097/PPO.0b013e31819e31cf
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi: 10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Broeckelmann PJ, Engert A. The GHSG approach to treating Hodgkin’s lymphoma. Curr Hematol Malig Rep. 2015;10(3):256–265. doi: 10.1007/s11899-015-0262-5
   PubMed Web of Science ®Google Scholar
• Zhu YJ, et al. Clinical characteristics and prognostic factors in Chinese patients with Hodgkin’s lymphoma. Med Oncol. 2012;29(2):1127–1133. doi: 10.1007/s12032-011-9902-3
   PubMed Web of Science ®Google Scholar
• Wan WL, et al. Clinical characteristics and prognostic factors of 62 cases with Hodgkin lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2013;34(7):618–621.
   PubMedGoogle Scholar
• Yang M, et al. Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: a retrospective study. Hematology. 2019;24(1):413–419. doi: 10.1080/16078454.2019.1598678
   PubMed Web of Science ®Google Scholar
• Ma J, et al. Clinical characteristics of 26 patients with primary extranodal Hodgkin lymphoma. Int J Clin Exp Pathol. 2014;7(8):5045–5050.
   PubMed Web of Science ®Google Scholar
• Cheson BD, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. doi: 10.1200/JCO.2006.09.2403
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. D. Int prognostic factors project Adv Hodgkins, a prognostic score for advanced Hodgkin’s disease. N Engl J Med. 1998;339(21):1506–1514. doi: 10.1056/NEJM199811193392104
   PubMed Web of Science ®Google Scholar
• Lister TA, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630–1636. doi: 10.1200/JCO.1989.7.11.1630
   PubMed Web of Science ®Google Scholar
• Li ZM, et al. Clinical characteristics of the patients with Hodgkin’s lymphoma involving extranodal sites. Chin J Cancer. 2012;31(7):342–347. doi: 10.5732/cjc.012.10008
   PubMedGoogle Scholar
• Iyengar P, et al. Hodgkin lymphoma involving extranodal and nodal head and neck sites: characteristics and outcomes. Cancer. 2010;116(16):3825–3829. doi: 10.1002/cncr.25138
   PubMed Web of Science ®Google Scholar
• Li YF, et al. Clinical characteristics of 30 Hodgkin’s lymphoma patients with extranodal involvement. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(3):712–716.
   PubMedGoogle Scholar
• Yao S, et al. Extranodal involvement in young patients with diffuse large B-cell lymphoma: distribution, prognostic value and treatment options. Chin J Cancer Res. 2017;29(1):57–65. doi: 10.21147/j.issn.1000-9604.2017.01.07
   PubMed Web of Science ®Google Scholar
• Diehl V, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348(24):2386–2395. doi: 10.1056/NEJMoa022473
   PubMed Web of Science ®Google Scholar
• Aleman BMP, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348(24):2396–2406. doi: 10.1056/NEJMoa022628
   PubMed Web of Science ®Google Scholar
• von Tresckow B, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol. 2012;30(9):907–913. doi: 10.1200/JCO.2011.38.5807
   PubMed Web of Science ®Google Scholar
• Moccia AA, et al. International prognostic score in advanced-stage Hodgkin’s lymphoma: altered utility in the Modern Era. J Clin Oncol. 2012;30(27):3383–3388. doi: 10.1200/JCO.2011.41.0910
   PubMed Web of Science ®Google Scholar
• Wang Q, et al. Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. Oncotarget. 2016;7(44):72219–72228.
   PubMedGoogle Scholar
• Vassilakopoulos TP, et al. Prognostic implication of the absolute lymphocyte to absolute monocyte count ratio in patients with classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens. Oncologist. 2016;21(3):343–353. doi: 10.1634/theoncologist.2015-0251
   PubMed Web of Science ®Google Scholar
• Alonso-Alvarez S, et al. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. Leuk Lymphoma. 2017;58(5):1144–1152. doi: 10.1080/10428194.2016.1239263
   PubMed Web of Science ®Google Scholar
• Wang Q, et al. Decreased prognostic value of international prognostic score in Chinese advanced Hodgkin lymphoma patients treated in the contemporary era. Chin Med J. 2016;129(23):2780–2785. doi: 10.4103/0366-6999.194661
   PubMed Web of Science ®Google Scholar
• Glimelius I, et al. Effect of eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines. Exp Hematol. 2011;39(8):850–858. doi: 10.1016/j.exphem.2011.05.006
   PubMed Web of Science ®Google Scholar
• Fernandez-Alvarez R, et al. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy. Leuk Lymphoma. 2015;56(11):3096–3102. doi: 10.3109/10428194.2015.1038709
   PubMed Web of Science ®Google Scholar
• Schreck S, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009;27(1):31–39. doi: 10.1002/hon.878
   PubMed Web of Science ®Google Scholar
• Alvaro-Naranjo T, et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin’s lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma. 2005;46(11):1581–1591. doi: 10.1080/10428190500220654
   PubMed Web of Science ®Google Scholar
• Aoki T, Steidl C. Novel biomarker approaches in classic Hodgkin lymphoma. Cancer J. 2018;24(5):206–214. doi: 10.1097/PPO.0000000000000334
   PubMed Web of Science ®Google Scholar